Skin disease is a serious and common problem in Ireland and the UK. Skin conditions are the fourth most common reason for GP visits in Ireland and skin cancer is the commonest form of cancer in Ireland.
The prevalence of skin diseases such as psoriasis, eczema, melanoma and skin cancer, and rosacea has increased steadily over the past 20 years. Today, between 25% and 33% of the Irish population suffers from a dermatological condition at any one time, while eight million people in the UK are living with a skin disease. As a result of these high incidences, Java has built up considerable experience in clinical trials of dermatological disorders.
Java Clinical Research is part of the EASY-Group CRO network, which includes dermatology specialists in proinnovera. With EASY-Group and proinnovera we are part of a Europe-wide network with huge experience in dermatology trials.
Through our affiliation with University College Dublin, we have access to highly experienced researchers in the area of dermatology.
Launched in June 2008, with an investment of €18 million, the Charles Institute at University College Dublin is the first academic institute devoted to dermatology in Ireland. The Institute’s vision is to become a world leader in dermatology research and training, which will lead to improved patient care through the discovery of new treatments and therapies.
At the Charles Institute it is hoped that the application of frontier biotechnologies will provide exciting opportunities to develop worthwhile new therapies for the ultimate benefit of the patient. These will include:
- Micro-therapeutics to generate new drugs for clinical research
- Stem cell therapy which focuses on regenerative medicine
- Tissue repair and wound healing
- Tissue engineering which involves the creation of artificial skin
- Nanobiology for the development of nanomaterials for drug and gene delivery
If you are considering a clinical trial on any aspect of Dermatology, why not tap into our expertise in this field?